戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 nt the next generation of oxazolidinones and lipoglycopeptides.
2 common to all glycopeptides (vancomycin) and lipoglycopeptides.
3 o a lipopeptide tail, and in the case of the lipoglycopeptides, a deoxymannose moiety.
4 ight into the enhanced activity of guanidino lipoglycopeptides against vancomycin-resistant isolates.
5               Oritavancin is a semisynthetic lipoglycopeptide analogue of vancomycin that contains th
6                               Dalbavancin, a lipoglycopeptide antibiotic agent that is active against
7 following exposure of the macrophages to the lipoglycopeptide antibiotic oritavancin.
8                             Oritavancin is a lipoglycopeptide antibiotic that has been shown to be ef
9                 Telavancin is a bactericidal lipoglycopeptide antibiotic that is active against a ran
10                              Telavancin is a lipoglycopeptide antibiotic with potent in vitro activit
11                             Oritavancin is a lipoglycopeptide antibiotic with rapid bactericidal acti
12 ubstantial intracellular accumulation with a lipoglycopeptide antibiotic.
13 diversification of the glycolipid portion of lipoglycopeptide antibiotics is simple to perform on a l
14                             Dalbavancin is a lipoglycopeptide antimicrobial agent with a potency sign
15            These findings position guanidino lipoglycopeptides as candidates for further development
16 , the present discovery of a family of novel lipoglycopeptides as potent inhibitors of bacterial SPas
17    The core structure of the arylomycins and lipoglycopeptides consists of a biaryl-linked, N-methyla
18                Telavancin is a semisynthetic lipoglycopeptide derivative of vancomycin.
19                   Mechanistically, guanidino lipoglycopeptides engaged with bacterial cell wall precu
20            The in vivo efficacy of guanidino lipoglycopeptide EVG7 was evaluated in a S. aureus murin
21 on of a family of structurally related novel lipoglycopeptides from a Streptomyces sp. as inhibitors
22  and became the first marketed semisynthetic lipoglycopeptide in 2009.
23                                  Long-acting lipoglycopeptides (laLGPs), such as dalbavancin and orit
24        Recently, the arylomycins and related lipoglycopeptide natural products were isolated and show
25 o beta-lactams, aminoglycosides, vancomycin, lipoglycopeptides, oxazolidinones, novel tetracycline-de
26 s, including MS and NMR, revealed that these lipoglycopeptides share a common 14-membered cyclic pept
27     Dalbavancin is a long-acting intravenous lipoglycopeptide that may be effective for treatment of
28               In contrast to prior work with lipoglycopeptides, this study reveals the glucose C3' or
29 etic glycopeptide antibiotics, the guanidino lipoglycopeptides, which contain a positively charged gu
30                             Oritavancin is a lipoglycopeptide with bactericidal activity against gram